Perspective Therapeutics News

Perspective Therapeutics Initiated at Outperform by RBC Capital

Perspective Therapeutics Initiated at Outperform by RBC Capital

Dow JonesMay 14 08:13 ET

Express News | RBC Capital Initiates Coverage On Perspective Therapeutics With Outperform Rating, Announces Price Target of $3

BenzingaMay 14 08:03 ET

Express News | Perspective Therapeutics Inc : RBC Initiates Coverage With Outperform Rating; Target Price $3

ReutersMay 14 01:56 ET

Express News | Perspective Therapeutics Inc : Cantor Fitzgerald Initiates Coverage With Overweight Rating

ReutersMay 9 06:07 ET

Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal

Seeking AlphaMay 2 14:31 ET

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced

GlobeNewswireMay 2 07:00 ET

Express News | FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors

BenzingaApr 30 07:20 ET

Compete for a new 10-billion-level racetrack! Global pharmaceutical giants grab the beach to lay out the nuclear medicine field

Morgan Stanley estimates that the radiopharmaceuticals market will grow from around $7 billion in 2022 to $39 billion by 2032.

Zhitong FinanceApr 12 09:35 ET

Perspective Therapeutics Is Maintained at Buy by B. Riley Securities

Perspective Therapeutics Is Maintained at Buy by B. Riley Securities

Dow JonesApr 9 13:57 ET

NYSE American New 52-Week Highs And Lows

New Highs 8 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Friedman Industries FRD 19.42 10,703 GA

Dow JonesApr 5 14:22 ET

Express News | Oppenheimer Reiterates Outperform on Perspective Therapeutics, Raises Price Target to $1.5

Moomoo 24/7Apr 1 09:27 ET

Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results

Yahoo FinanceMar 30 05:31 ET

Express News | Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?

Moomoo 24/7Mar 28 13:49 ET

Express News | Perspective Therapeutics FY2023 EPS $(0.14) Down From $(0.06) YoY, Sales $1.43M

Moomoo 24/7Mar 28 07:35 ET

Perspective Therapeutics: Runway To Fund Operations, Capital Investments Into 2026 >CATX

Perspective Therapeutics: Runway To Fund Operations, Capital Investments Into 2026 >CATX

Dow JonesMar 28 07:32 ET

Perspective Therapeutics 2023 Cont Ops Loss/Shr 14c >CATX

Perspective Therapeutics 2023 Cont Ops Loss/Shr 14c >CATX

Dow JonesMar 28 07:31 ET

Press Release: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN:

Dow JonesMar 28 07:30 ET

Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)

TipRanksMar 27 12:30 ET

Buy Rating Affirmed for Perspective Therapeutics Amid Clinical Success and Strategic Partnerships

TipRanksMar 21 07:27 ET

Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal -- WSJ

AstraZeneca became the latest big pharma to buy a company focused on an emerging approach to fighting cancer known as radiopharmaceuticals.

WSJMar 19 11:04 ET